Neurocrine Biosci…
USUSDNeurocrine Biosciences Inc (US:NBIX) — Biotechnology: Biological Products (No Diagnostic Substances). Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 3. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- neurocrine.com
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Hauptsitz
- San Diego, United States
- CEO
- Kyle W. Gano
- Mitarbeiter
- 2 500
- Gegründet
- 1992
- Ausstehende Aktien
- 101.65 Mio. Stand 2026-07-22
- Streubesitz
- 100.37 Mio.
- Marktkapitalisierung
- 14.42 Mrd. USD
- Insider
- 1.06%
- Institutionelle Anleger
- 102.84%
- Branche (SIC)
- Biological Products, (No Diagnostic Substances)
- Rechtsform
- XTIQ
- ISIN
- US64125C1099
- LEI
- 549300FECER0XBN49756
- FCF
- 870 Mio. USD
- Schulden
- 0
- Gewinne und FCF – für die 12 Monate bis 30.06.2026 (aktueller Bericht des Unternehmens).
Beschreibung
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Neuigkeiten diese Woche
Noch keine Nachrichten von der Website des Unternehmens.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| Blackrock Inc. | 13.49% | 13.71 Mio. | 2026-06-30 |
| JPMORGAN CHASE & CO | 6.29% | 6.4 Mio. | 2026-06-30 |
| Dodge & Cox Inc. | 5.49% | 5.58 Mio. | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.89% | 4.97 Mio. | 2026-06-30 |
| Vanguard Capital Managem… | 4.47% | 4.55 Mio. | 2026-06-30 |
| State Street Corporation | 4.31% | 4.39 Mio. | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 3.9% | 3.96 Mio. | 2026-06-30 |
| AQR Capital Management,… | 3.76% | 3.82 Mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 3.46% | 3.52 Mio. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 3.14% | 3.19 Mio. | 2026-06-30 |
| Renaissance Technologies… | 2.3% | 2.34 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.27% | 2.3 Mio. | 2026-06-30 |
| Geode Capital Management… | 2.1% | 2.14 Mio. | 2026-06-30 |
| Two Sigma Investments, L… | 2.04% | 2.08 Mio. | 2026-06-30 |
| J.P. Morgan Mutual Fd. I… | 1.34% | 1.36 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.31% | 1.33 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.13% | 1.15 Mio. | 2026-06-30 |
| JPMorgan Trust II-JPMorg… | 1.1% | 1.12 Mio. | 2026-06-30 |
| iShares Trust-iShares Bi… | 0.73% | 739 670 | 2026-08-31 |
| SPDR S&P MIDCAP 400 ETF… | 0.72% | 735 342 | 2026-08-31 |
| GORMAN KEVIN CHARLES (Di… | ≈0.51% | 517 797 | 2026-09-11 |
| GANO KYLE W (Chief Execu… | ≈0.15% | 154 728 | 2026-09-11 |
| LYONS GARY A (Director) | ≈0.12% | 122 141 | 2026-05-21 |
| BENEVICH ERIC S. (Office… | ≈0.07% | 67 297 | 2026-09-11 |
| LIPPOLDT DARIN M (Office… | ≈0.06% | 56 793 | 2026-09-11 |
| RASTETTER WILLIAM H (Dir… | ≈0.04% | 43 678 | 2026-05-21 |
| ABERNETHY MATTHEW C (Chi… | ≈0.04% | 42 808 | 2026-09-14 |
| POPS RICHARD F (Director… | ≈0.04% | 37 798 | 2026-05-21 |
| ROBERTS EIRY WYN (Office… | ≈0.04% | 35 640 | 2025-02-14 |
| COOKE JULIE SMITH (Offic… | ≈0.02% | 24 025 | 2026-09-11 |